FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Claudio Denzlinger

Research Profile

Chemicals & Drugs

Anatomy

Disorders

Concepts & Ideas

Survival Analysis

Procedures

Antineoplastic Combined Chemotherapy Protocols

Co-author Network

Publications

TOP 3
Frédéric Baron; Sergio Amadori; Michel Delforge; Claudio Denzlinger; Karel Indrak; Petra Muus; Gert Ossenkoppele; Dominik Selleslag; Stefan Suciu; Antoine Thyss; Heinz Zwierzina; Theo de Witte
Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group.
Holger G Hass; Thomas Hehr; Christina Jäger; Hans-Ulrich Markmann; Oliver Nehls; Michael Schäffer; Ute Smith; Ulrich Wellhäuber; Claudio Denzlinger
Signet ring cell carcinoma of the stomach is significantly associated with poor prognosis and diffuse gastric cancer (Lauren's): single-center experience of 160 cases.
Clemens Giessen; Philipp Aubele; Markus Bangerter; Claudio Denzlinger; Jens Freiberg-Richter; Axel Hinke; Frank Kullmann; Julia Mayerle; Dominik Paul Modest; Nicolas Moosmann; Christoph Schulz; Markus Sieber; Sebastian Stintzing; Christian Teschendorf; Ursula Vehling-Kaiser; Ludwig Fischer von Weikersthal; Volker Heinemann
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Claudio Denzlinger (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Frédéric Baron; Sergio Amadori; Michel Delforge; Claudio Denzlinger; Karel Indrak; Petra Muus; Gert Ossenkoppele; Dominik Selleslag; Stefan Suciu; Antoine Thyss; Heinz Zwierzina; Theo de Witte
Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group.
Haematologica 2012;97(4):529-33.
2011: Holger G Hass; Thomas Hehr; Christina Jäger; Hans-Ulrich Markmann; Oliver Nehls; Michael Schäffer; Ute Smith; Ulrich Wellhäuber; Claudio Denzlinger
Signet ring cell carcinoma of the stomach is significantly associated with poor prognosis and diffuse gastric cancer (Lauren's): single-center experience of 160 cases.
Onkologie 2011;34(12):682-6.
2011: Clemens Giessen; Philipp Aubele; Markus Bangerter; Claudio Denzlinger; Jens Freiberg-Richter; Axel Hinke; Frank Kullmann; Julia Mayerle; Dominik Paul Modest; Nicolas Moosmann; Christoph Schulz; Markus Sieber; Sebastian Stintzing; Christian Teschendorf; Ursula Vehling-Kaiser; Ludwig Fischer von Weikersthal; Volker Heinemann
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
BMC cancer 2011;11():367.
2009: Andreas M Boehmler; Adriana Drost; Lena Jaggy; Gabriele Seitz; Tina Wiesner; Claudio Denzlinger; Lothar Kanz; Robert Möhle
The CysLT1 ligand leukotriene D4 supports alpha4beta1- and alpha5beta1-mediated adhesion and proliferation of CD34+ hematopoietic progenitor cells.
Journal of immunology (Baltimore, Md. : 1950) 2009;182(11):6789-98.
2005: Sergio Amadori; Stefan Suciu; Roberto Stasi; Rein Willemze; Franco Mandelli; Dominik Selleslag; Claudio Denzlinger; Petra Muus; R Stauder; Zwi Berneman; J Pruijt; Francesco Nobile; V Cassibba; Jean-Pierre Marie; Filip Beeldens; L Baila; Marco Vignetti; Theo de Witte
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.
Leukemia 2005;19(10):1768-73.
2005: Sergio Amadori; Stefan Suciu; Ulrich Jehn; Roberto Stasi; Xavier Thomas; Jean-Pierre Marie; Petra Muus; Francois Lefrère; Zwi Berneman; George Fillet; Claudio Denzlinger; Rein Willemze; Pietro Leoni; Giuseppe Leone; Marco Casini; Francesco Ricciuti; Marco Vignetti; Filip Beeldens; Franco Mandelli; Theo de Witte
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study.
Blood 2005;106(1):27-34.
2004: Sergio Amadori; Stefan Suciu; Rein Willemze; Franco Mandelli; Dominik Selleslag; Reinhard Stauder; Anthony Ho; Claudio Denzlinger; Giuseppe Leone; Piero Fabris; Petra Muus; Marco Vignetti; Anne Hagemeijer; Filip Beeldens; Ozlem Anak; Theo de Witte
Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.
Haematologica 2004;89(8):950-6.
2004: Helmut R Salih; Volkmar Nuessler; Claudio Denzlinger; Gary C Starling; Peter Kiener; Helga Schmetzer
Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome.
Leukemia & lymphoma 2004;45(2):301-8.
2003: Alessio Nencioni; Kirsten Lauber; Frank Grünebach; Luk Van Parijs; Claudio Denzlinger; Sebastian Wesselborg; Peter Brossart
Cyclopentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(10):5148-56.
2003: Ingrid Beck-Speier; Niru Dayal; Claudio Denzlinger; Christopher Haberl; Konrad L Maier; Axel Ziesenis; Joachim Heyder
Sulfur-related air pollutants induce the generation of platelet-activating factor, 5-lipoxygenase- and cyclooxygenase-products in canine alveolar macrophages via activation of phospholipases A2.
Prostaglandins & other lipid mediators 2003;71(3-4):217-34.
2003: Robert Mohle; Andreas M Boehmler; Claudio Denzlinger; Lothar Kanz
Nonpeptide mediators in the hematopoietic microenvironment.
Annals of the New York Academy of Sciences 2003;996():61-6.
2003: Andreas M Boehmler; Claudio Denzlinger; Lothar Kanz; Robert Möhle
Potential role of cysteinyl leukotrienes in trafficking and survival of hematopoietic progenitor cells.
Advances in experimental medicine and biology 2003;525():25-8.
2002: Alessio Nencioni; Kirsten Lauber; Frank Grünebach; Wolfram Brugger; Claudio Denzlinger; Sebastian Wesselborg; Peter Brossart
Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-gamma-independent mechanism: regulation by inflammatory and T cell-derived stimuli.
Experimental hematology 2002;30(9):1020-8.
2002: Markus P Radsak; Helmut R Salih; M Sökler; L Kanz; Claudio Denzlinger
Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance.
Leukemia 2002;16(9):1870-1.
2002: Alessio Nencioni; Frank Grünebach; Anke Zobywlaski; Claudio Denzlinger; Wolfram Brugger; Peter Brossart
Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(3):1228-35.
2002: Raphaela Waidelich; Ernst Weninger; Claudio Denzlinger; Ulrike L Müller-Lisse; Alfons Hofstetter; Nikolaus Schmeller
Use of veno-venous bypass for resection of malignant pheochromocytoma with vena caval thrombus.
International urology and nephrology 2002;34(2):241-3.
2001: Robert Möhle; F Bautz; Claudio Denzlinger; Lothar Kanz
Transendothelial migration of hematopoietic progenitor cells. Role of chemotactic factors.
Annals of the New York Academy of Sciences 2001;938():26-34; discussion 34-5.
2001: F Bautz; Claudio Denzlinger; Lothar Kanz; Robert Möhle
Chemotaxis and transendothelial migration of CD34(+) hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1.
Blood 2001;97(11):3433-40.
2001: M Manz; Reimer Riessen; L Poll; Bernhard M Dohmen; E Kaiserling; W Krück; M Laniado; Lothar Kanz; Claudio Denzlinger
High-grade lymphoma mimicking bone crisis in Gaucher's disease.
British journal of haematology 2001;113(1):191-3.
2000: Claudio Denzlinger; D Bowen; Dietmar Benz; KJ Gelly; Wolfram Brugger; Lothar Kanz
Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia.
British journal of haematology 2000;108(1):93-5.
1999: Michael Schleuning; Gabriele Jäger; Ernst Holler; W Hill; C Thomssen; Claudio Denzlinger; T Lorenz; Georg Ledderose; W Wilmanns; Hans-Jochem Kolb
Human parvovirus B19-associated disease in bone marrow transplantation.
Infection 1999;27(2):114-7.
1998: D T Bowen; Claudio Denzlinger; Wolfram Brugger; D Culligan; KJ Gelly; S Adlakha; M Groves; MD Hepburn; Lothar Kanz
Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patients.
British journal of haematology 1998;103(3):785-7.
1998: Ingrid Beck-Speier; Niru Dayal; Claudio Denzlinger; Christopher Haberl; Konrad L Maier
Sulfite induces release of lipid mediators by alveolar macrophages.
Zeitschrift für Naturforschung. C, Journal of biosciences 1998;53(3-4):264-72.
1998: S Geuenich; Christopher Haberl; D Egger; U Kaspers; Lothar Hültner; W Wilmanns; Claudio Denzlinger
Induction of leukotriene production by bleomycin and asparaginase in mast cells in vitro and in patients in vivo.
Biochemical pharmacology 1998;55(4):447-53.
1998: Claudio Denzlinger
[Leukotrienes promote inflammation and proliferation. Interaction with other mediator systems--modulation by therapeutic measures].
Fortschritte der Medizin 1998;116(3):41.
1998: Christopher Haberl; Lothar Hültner; A Flügel; M Falk; S Geuenich; W Wilmanns; Claudio Denzlinger
Release of prostaglandin D2 by murine mast cells: importance of metabolite formation for antiproliferative activity.
Mediators of inflammation 1998;7(2):79-84.
1998: Klaus Dittmann; C Mayer; H Peter Rodemann; P E Petrides; Claudio Denzlinger
MK-886, a leukotriene biosynthesis inhibitor, induces antiproliferative effects and apoptosis in HL-60 cells.
Leukemia research 1998;22(1):49-53.
1997: Volkmar Nuessler; Renate Pelka-Fleischer; Heinz Zwierzina; W Wilmanns; Claudio Denzlinger
Effects of progesterone and leukotriene receptor antagonists in experimental models of P-glycoprotein-related resistance.
European journal of medical research 1997;2(4):159-64.
1996: Claudio Denzlinger
Biology and pathophysiology of leukotrienes.
Critical reviews in oncology/hematology 1996;23(3):167-223.
1995: Olaf Adam; C Lemmen; T Kless; P Adam; Claudio Denzlinger; S Hailer
Low fat diet decreases alpha-tocopherol levels, and stimulates LDL oxidation and eicosanoid biosynthesis in man.
European journal of medical research 1995;1(2):65-71.
1995: Claudio Denzlinger; Christopher Haberl; W Wilmanns
Cysteinyl leukotriene production in anaphylactic reactions.
International archives of allergy and immunology 1995;108(2):158-64.
1995: Claudio Denzlinger; M Humann; W Steiner; J Bader; L Greither; W Günther; Gilbert Reisbach; R Munker; R Baumgart; M Leeping
[54-year-old patient with anemia, jaundice, hepatosplenomegaly and paravertebral space-occupying lesions].
Der Internist 1995;36(7):726-9.
1995: W Steiner; Claudio Denzlinger; M Weiss
[Paravertebral extramedullary hematopoiesis in congenital dyserythropoietic anemia type II (CDA II)].
Röntgenpraxis; Zeitschrift für radiologische Technik 1995;48(4):110-2.
1995: Christopher Haberl; Claudio Denzlinger
[Leukotriene in physiopathology of systemic mastocytosis].
Deutsche medizinische Wochenschrift (1946) 1995;120(13):463.
1995: Claudio Denzlinger; T Kless; S Sagebiel-Kohler; C Lemmen; K Jacob; W Wilmanns; Olaf Adam
Modulation of the endogenous leukotriene production by fish oil and vitamin E.
Journal of lipid mediators and cell signalling 1995;11(2):119-32.
1995: D Egger; S Geuenich; Claudio Denzlinger; E Schmitt; R Mailhammer; Hannelore Ehrenreich; Peter Dörmer; Lothar Hültner
IL-4 renders mast cells functionally responsive to endothelin-1.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(4):1830-7.
1994: Claudio Denzlinger; Ernst Holler; Gilbert Reisbach; E Hiller; W Wilmanns
Granulocyte colony-stimulating factor inhibits the endogenous leukotriene production in tumour patients.
British journal of haematology 1994;86(4):881-2.
1993: Claudio Denzlinger; J Walther; W Wilmanns; HH Gerhartz
Interleukin-3 enhances the endogenous leukotriene production.
Blood 1993;81(9):2466-8.
1993: Claudio Denzlinger; W Tetzloff; HH Gerhartz; R Pokorny; S Sagebiel; Christopher Haberl; W Wilmanns
Differential activation of the endogenous leukotriene biosynthesis by two different preparations of granulocyte-macrophage colony-stimulating factor in healthy volunteers.
Blood 1993;81(8):2007-13.
1993: Claudio Denzlinger; J Walther; W Wilmanns; HH Gerhartz
Interleukin-3 enhances the endogenous leukotriene production.
Blood 1993;81(7):1975-6.
1991: Claudio Denzlinger; M Grimberg; A Kapp; Christopher Haberl; W Wilmanns
Effect of the leukotriene receptor antagonists FPL 55712, LY 163443, and MK-571 on the elimination of cysteinyl leukotrienes in the rat.
British journal of pharmacology 1991;102(4):865-70.
1991: Rolf Issels; J Mittermüller; Arthur Gerl; W Simon; A Ortmaier; Claudio Denzlinger; H Sauer; W Wilmanns
Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients.
Journal of cancer research and clinical oncology 1991;117 Suppl 4():S141-7.
1990: Claudio Denzlinger; A Kapp; M Grimberg; HH Gerhartz; W Wilmanns
Enhanced endogenous leukotriene biosynthesis in patients treated with granulocyte-macrophage colony-stimulating factor.
Blood 1990;76(9):1765-70.